Cyrta, Joanna
Augspach, Anke
De Filippo, Maria Rosaria
Prandi, Davide
Thienger, Phillip
Benelli, Matteo http://orcid.org/0000-0003-1227-356X
Cooley, Victoria
Bareja, Rohan
Wilkes, David http://orcid.org/0000-0002-2422-1145
Chae, Sung-Suk
Cavaliere, Paola
Dephoure, Noah
Uldry, Anne-Christine
Lagache, Sophie Braga
Roma, Luca
Cohen, Sandra
Jaquet, Muriel
Brandt, Laura P.
Alshalalfa, Mohammed http://orcid.org/0000-0001-8405-3035
Puca, Loredana
Sboner, Andrea
Feng, Felix http://orcid.org/0000-0002-0963-7687
Wang, Shangqian
Beltran, Himisha http://orcid.org/0000-0003-3259-2226
Lotan, Tamara
Spahn, Martin
Kruithof-de Julio, Marianna http://orcid.org/0000-0002-6085-7706
Chen, Yu http://orcid.org/0000-0002-0171-3884
Ballman, Karla V.
Demichelis, Francesca http://orcid.org/0000-0002-8266-8631
Piscuoglio, Salvatore
Rubin, Mark A. http://orcid.org/0000-0002-8321-9950
Article History
Received: 8 February 2020
Accepted: 7 October 2020
First Online: 3 November 2020
Competing interests
: H.B. has received research funding from Janssen, Astellas, Abbvie, Millennium, and Eli Lilly and consulting with Janssen, Astellas, Sanofi Genzyme, Astra Zeneca, Pfizer. L.P. is now an employee of Loxo Oncology at Lilly. M.A.R. has received research funding from Novartis, Roche, Ventana, Janssen, Astellas, Millennium, and Eli Lilly. M.A.R. is on the SAB of Neogenomics. T.L.L. has received research funding from DeepBio, Decipher, Ventana/Roche. Cornell and Bern Universities have filed a patent application on SWI/SNF diagnostic and therapeutic fields with A.A., J.C., and M.A.R. listed as inventors. The remaining authors declare no competing interests.